MedTrace Logo

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

NCT00941356 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-07-22

No results posted yet for this study

Summary

Trial Objectives:

Primary objective:

* To evaluate the efficacy of Bio-K+CL1285® in patients with Methicillin-Resistant S. aureus (MRSA) nasal colonization by comparing the MRSA decolonization following either Bio-K+CL1285® or placebo treatment.

Secondary objective:

* To evaluate the safety profile of Bio-K+CL1285®.

Conditions

  • MRSA Colonization

Interventions

DIETARY_SUPPLEMENT

Bio-K+ CL1285

2 capsules per day before breakfast

DIETARY_SUPPLEMENT

Placebo

2 capsules per day before breakfast

Sponsors & Collaborators

  • Centre Hospitalier Pierre-Le Gardeur

    collaborator UNKNOWN

  • Bio-K Plus International Inc.

    lead INDUSTRY

Principal Investigators

  • Dr Pierre-Jean PM Maziade, MD · Pierre Le Gardeur Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941356 on ClinicalTrials.gov